People: AEterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

0.55USD
4 May 2015
Change (% chg)

-- (--)
Prev Close
$0.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,180,057
52-wk High
$1.54
52-wk Low
$0.48

Search Stocks

Dodd, David 

Mr. David A. Dodd is Chairman of the Board, President, Chief Executive Officer of Aeterna Zentaris Inc. Mr. Dodd's executive management experience in the pharmaceutical and biotechnology industries spans more than 35 years. Prior to joining Aeterna Zentaris, Mr. Dodd was President and CEO of Solvay Pharmaceuticals, Inc. During his six-year tenure as President, CEO and Director of Serologicals Corporation, the market value of the company increased from $85 million in June 2000 to an all-cash sale to Millipore Corporation in July 2006 for $1.5 billion. He also was President, CEO and Chairman of BioReliance Corporation, a leading provider of biological safety and related testing services. Prior to that, Mr. Dodd held various senior management positions at Wyeth-Ayerst Laboratories, the Mead Johnson Laboratories Division at Bristol-Myers Squibb, and Abbott Laboratories. Mr. Dodd holds a Master degree from Georgia State University, and completed the Harvard Business School Advanced Management Program.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
378,846 -- 486,106 1,279,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Dodd

1,279,000

Dennis Turpin

403,092

Philip Theodore

--

Richard Sachse

--

Jude Dinges

259,884

Keith Santorelli

--
As Of  30 Dec 2013
Search Stocks